Publication at First Faculty of Medicine |
2007
Abstract
We investigated the potential use of idraparinux, a long-acting inhibitor of activated factor X, as a substitute for standard therapy. Methods: We conducted two randomized, open-label noninferiority trials involving 2904 patients with deep-vein thrombosis and 2215 patients with pulmonary embolism to compare the efficacy and safety of idraparinux versus standard therapy.